No Additional Omapro Trials Needed, U.S. FDA Tells Australian ChemGenex In Complete Response Letter
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australian-headquartered ChemGenex received a complete response letter from U.S. FDA for its new drug application for Omapro (omacetaxine mepesuccinate) for chronic myeloid leukemia, and the company is breathing a sigh of relief that it will not have to conduct additional trials or enroll additional patients, ChemGenex said April 12
You may also be interested in...
Australian ChemGenex Readies Omapro For Second NDA Despite U.S. FDA Setbacks
PERTH, Australia - Australian-headquartered ChemGenex has completed pivotal trials for Omapro for third-line treatment for chronic myeloid leukemia for patients who have failed multiple tyrosine kinase inhibitors; the company expects to file its application with U.S. FDA while its NDA for second-line treatment for CML in patients with the Brc-Abl T315I is still under review
Australian ChemGenex Readies Omapro For Second NDA Despite U.S. FDA Setbacks
PERTH, Australia - Australian-headquartered ChemGenex has completed pivotal trials for Omapro for third-line treatment for chronic myeloid leukemia for patients who have failed multiple tyrosine kinase inhibitors; the company expects to file its application with U.S. FDA while its NDA for second-line treatment for CML in patients with the Brc-Abl T315I is still under review
U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro
Australian-headquartered ChemGenex has agreed to meet with U.S. FDA in April to begin developing a validated assay test for determining which patients might benefit from its experimental chronic myeloid leukemia treatment Omapro.